Friday, September 05, 2008 Free Registration Log-in to View Profiles
Empire Relations Group is a Premier Investor Relations Organization representing publicly-traded companies in their communications programs with existing shareholders and potential investors.
investments
OTCBB
OTCBB
Pressroom 
 
 Archived
 
 Non-Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
 
 Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
Search


Public Companies : Healthcare/BioTech


Warnex Launches New Paternity Testing Website: www.prodna.ca

Jun 26, 2008 - 3:36:01 PM

News Source MARKET WIRE

Email this article
 Printer friendly page
LAVAL, QUEBEC -- (MARKET WIRE) -- 06/26/08 -- Warnex Inc. (TSX: WNX) announced today the launch of its new website www.prodna.ca for its DNA identification tests, including the PRO-DNA(TM) Paternity Test.

PRO-DNA identification tests offer a clear, unequivocal answer. Using advanced DNA technology and validated procedures, Warnex offers identification tests of superior quality and reliability while using a simple, painless type of sampling procedure that can be performed easily at home. In addition to the paternity test, Warnex offers DNA tests to determine maternity, twin zygosity, other family relationships, as well as forensic testing and genetic profiling.

"Our DNA tests offer results that are highly reliable and with an accuracy of over 99.95%," said Mark Busgang, President and CEO of Warnex. "Warnex is the leading provider of DNA identification tests in Quebec as well, the Quebec Commission des Services Juridiques and many leading law firms regularly refer clients to us."

In addition to genetic identification testing, Warnex Medical Laboratories offers specialized clinical services to the healthcare and pharmaceutical industries. Testing services include biochemical, microbiological and molecular biology testing in a wide range of clinical specialties, including: endocrinology, haematology, infectious diseases, obstetrics/gynaecology, and oncology.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex's analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

PRO-DNA is a trademark of Warnex Inc., Laval, Quebec.

Contacts:
Warnex Inc.
Mark J. Busgang
President & CEO
450-663-6724 x 310
mbusgang@warnex.ca

Warnex Inc.
Catherine Sartoros
Communications Specialist
450-663-6724 x 277
csartoros@warnex.ca



Top of Page | Main News Index | EmpireRelations.com Home Page EmpireRelations.com Selected Clients News

Come see our services. Copr. © 2005 Empire Relations Group, Inc.

Healthcare/BioTech
Latest Headlines
CLX Medical, Inc. Issues August 2008 Newsletter Highlighting Planned Acquisition of the ThyroTest(R) Rapid Screening Device
New Director of Operations Announced at MIHS
SinoFresh(R) Nasal Spray Kills MRSA "Super-Bug" in Live Noses
Smith & Nephew Plc - Transaction in Own Shares
Oncologix Announces Signing of Asset Purchase Agreement Pertaining to Selling Its Oncosphere Assets
Clinical Studies Completed for HeartVue's 6S Heart Screening System
Trimedyne Enters Into Letter of Intent With FemSuite, LLC
Forbes Medi-Tech Announces Sale of Pharmaceutical Assets
Stellar Pharmaceuticals Inc. Announces Successful Completion of Watson's Pilot Clinical Study
MethylGene Provides Update on Suspension of New Enrollment in MGCD0103 Clinical Trials